Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma

Article English OPEN
Tracy A. Marko ; Ghaidan A. Shamsan ; Elizabeth N. Edwards ; Paige E. Hazelton ; Susan K. Rathe ; Ingrid Cornax ; Paula R. Overn ; Jyotika Varshney ; Brandon J. Diessner ; Branden S. Moriarity ; M. Gerard O’Sullivan ; David J. Odde ; David A. Largaespada (2016)
  • Publisher: Nature Publishing Group
  • Journal: Scientific Reports, volume 6 (issn: 2045-2322, eissn: 2045-2322)
  • Related identifiers: pmc: PMC5155223, doi: 10.1038/srep39059
  • Subject: Article
    mesheuropmc: neoplasms | musculoskeletal diseases

Osteosarcoma is the most common primary bone tumor, with metastatic disease responsible for most treatment failure and patient death. A forward genetic screen utilizing Sleeping Beauty mutagenesis in mice previously identified potential genetic drivers of osteosarcoma metastasis, including Slit-Robo GTPase-Activating Protein 2 (Srgap2). This study evaluates the potential role of SRGAP2 in metastases-associated properties of osteosarcoma cell lines through Srgap2 knockout via the CRISPR/Cas9 nuclease system and conditional overexpression in the murine osteosarcoma cell lines K12 and K7M2. Proliferation, migration, and anchorage independent growth were evaluated. RNA sequencing and immunohistochemistry of human osteosarcoma tissue samples were used to further evaluate the potential role of the Slit-Robo pathway in osteosarcoma. The effects of Srgap2 expression modulation in the murine OS cell lines support the hypothesis that SRGAP2 may have a role as a suppressor of metastases in osteosarcoma. Additionally, SRGAP2 and other genes in the Slit-Robo pathway have altered transcript levels in a subset of mouse and human osteosarcoma, and SRGAP2 protein expression is reduced or absent in a subset of primary tumor samples. SRGAP2 and other axon guidance proteins likely play a role in osteosarcoma metastasis, with loss of SRGAP2 potentially contributing to a more aggressive phenotype.
Share - Bookmark